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Abstract 
Atherosclerosis is a leading cause of death worldwide. It is a complex chronic inflammatory 
disease involving interactions between vascular, circulating and immune cells. B cells play an 
important role in chronic inflammation producing antibodies and regulating T and natural 
killer (NKT) cell activation. The role of B cells in atherosclerosis is complex, with atherogenic 
and protective roles assigned for distinct B cell subsets. Drugs that deplete B cells or 
modulate their functions are now used in the treatment of various autoimmune diseases in 
humans. Here, we briefly review the roles of B cell subsets in atherogenesis, and emphasize 
the potential impact of B cell targeted therapies on the cardiovascular risk of treated patients. 
Developing more B cell subset-specific therapies would lead to more effective treatments 
with enhanced safety profile. 
 
Atherosclerosis and immune response 
 
Atherosclerotic artery disease is the leading cause of death and morbidity worldwide. 
Atherosclerosis is a complex inflammatory disease of the large and medium-sized blood 
vessels with multiple genetic and environmental risk factors. It is initiated in response to 
trapping of low-density lipoproteins (LDL) in the intima. LDL will then acquire immunogenic 
properties through both enzymatic and non-enzymatic modifications. The subsequent 
immune response involves interactions between many vascular (endothelial cells, smooth 
muscle cells, etc.) and immune cells (lymphocytes, myeloid cells, etc.), leading to a chronic 
inflammatory state that, in the absence of effective counter-regulatory mechanisms, will 
evolve to plaque disruption and vessel thrombosis ending in an acute ischemic (cardiac, 
cerebrovascular, etc.) event.  
Nearly all of innate and adaptive immune cells have been implicated in 
atherogenesis. Murine and human atherosclerotic plaques contain macrophages, dendritic 
cells (DC), mast cells, T and B lymphocytes in the intima and adventitia (reviewed in 
(Hansson and Hermansson, 2011). Following intimal trapping of LDL and activation of the 
endothelial cell layer, resident and monocyte-derived macrophages will further promote 
atherosclerotic lesion development through foam cell formation and activation of the 
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inflammatory response. Dendritic cells and T cells become activated both locally and 
systemically in response to several atherosclerosis-related antigens, mainly derived from 
lipoproteins, and further contribute to the modulation of the immune response and the 
development of atherosclerosis. B cells accumulate only in small numbers in atherosclerotic 
plaques, while they are quite abundant in artery tertiary lymphoid organs (ATLO). ATLOs are 
complex and organized immune cell aggregates (T and B lymphocytes, and plasma cells) 
that infiltrate the adventitia at sites of advanced atherosclerotic plaques, and are capable of 
mounting local immune responses. Their exact role in atherosclerosis has not been 
deciphered yet, although some atheroprotective roles have been described (Yin et al., 2016). 
B cells in secondary lymphoid organs also contribute to the immune responses of 
atherosclerosis. 
 
B cells and atherosclerosis 
 
B cells play important roles in both innate and adaptive humoral and cellular immune 
responses. They are the only cells able to undergo hypersomatic mutations and become 
antibody-producing cells (germinal centre, plasmablasts and plasma cells). Antibodies are 
glycoproteins of the immunoglobulin family that are attached to the B cell membranes serving 
as B cell receptor (BCR) for antigens or can be secreted into the extracellular space and the 
circulation where they bind to auto- or foreign antigens. There are five main immunoglobulin 
classes (M, D, A, E and G) that are distinguishable by their different C-terminus region of the 
heavy chain (Fc). IgM antibodies are atheroprotective, while adaptive IgE and IgG antibodies 
are considered pro-atherogenic, even though contrasting data have been published for the 
latter (reviewed in (Tsiantoulas et al., 2014)). For many years, B cells were believed to 
participate exclusively in the humoral immune response of atherosclerosis, but we now know 
that they also have a prominent role in the cellular response by directly regulating T cell 
activation via antigen presentation, co-stimulation and cytokine production.   
There are several B cell subsets. On one hand, B-1 cell subset comprises the main B 
cell population in the peritoneal and pleural cavities, while it is a relatively small population 
(expressing CD43+) in the spleen. B-1 cells participate in the innate immune response and 
they are specialized in secreting high amount of natural IgM antibodies. On the other hand, 
B2 cells comprise the phenotypically distinct follicular (FO) B cells of the spleen and the 
lymph nodes, and the marginal zone (MZ) B cell population of the spleen. They contribute to 
both innate (MZ B cells) and adaptive (FO and MZ B cells) immune responses. Finally, new 
B cell activating factor (BAFF) receptor-dependent B cell subsets that share phenotypic 
characteristics of B-1 and B2 (mostly MZB) cells have been discovered and classified based 
on their cytokine production profile. Innate response activator (IRA) B cells secrete high 
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amounts of granulocyte-macrophage colony-stimulating factor (GM-CSF) (Rauch et al., 
2012), and the regulatory B (Breg) cells that produce either interleukin (IL)-10 (B10) and/or 
IL-35 and dampen (auto)immune responses (Fillatreau, 2016) (Figure 1).  
The implication of B cells in atherosclerosis was demonstrated 15 years ago, when 
two different groups demonstrated that atherosclerotic mice with complete or splenic-
restricted B cell deficiency developed exacerbated atherosclerosis, suggesting that B cells 
were atheroprotective (Caligiuri et al., 2002; Major et al., 2002). Nevertheless, subsequent 
studies made by us and others targeting different B cell subsets challenged the overall 
atheroprotective concept of B cells, and B2 cells were assigned a detrimental role (Ait-
Oufella et al., 2010; Kyaw et al., 2012, 2010; Sage et al., 2012) in contrast to B-1 cells which 
were shown to be atheroprotective (Kyaw et al., 2011). We have further refined this concept, 
and demonstrated that within the B2 cell population, a distinction should be made between 
atherogenic FOB cells and atheroprotective MZB cells (Nus et al., 2017). Moreover, an 
atherogenic role has been assigned to IRA-B cells (Hilgendorf et al., 2014), whereas the role 
of Bregs remains controversial (Sage et al., 2015; Strom et al., 2015). Thus, it becomes clear 
that B cell subsets have a differential impact in atheroma development that is also influenced 
by the environmental niche and stage of disease development. 
Antibody production has been considered the hallmark of the protective effect of B 
cells in atherosclerosis. Thus, several translational studies have tried to find associations 
between atherosclerosis and circulating levels of ‘atheroprotective’ IgM and ‘atherogenic’ IgG 
antibody titres in humans. Reproducibly, low circulating IgM levels have been negatively 
correlated with the extent of atherosclerosis and CV events.  However, studies on IgG 
antibody titres against OxLDL or MDA-LDL showed positive, negative or no correlation with 
atherosclerosis (reviewed in (Zhang et al., 2015)) urging for new studies to elucidate their 
roles in atherosclerosis. In contrast, very few clinical studies have addressed the association 
between B cells and atherogenesis beyond antibodies. One of the main reasons for this is 
the difficulty to identify B cell subsets in humans that are strictly equivalent to murine B cells, 
particularly B1 cells. In a genome wide association experiment using data from subjects 
included in the Framingham Study and comparing them to published human and murine 
GWAS studies, genes related to B cell activation were shown to be enriched in control vs 
coronary heart disease patients, suggesting that B cells may confer protection for CVD 
(Huan et al., 2013). In another association study, `pro-atherogenic` CD19+CD86+ B cells 
were positively correlated, while ‘atheroprotective’ CD19+CD40+ cells were negatively 
correlated with the risk of developing stroke, despite no association with carotid intima-media 
thickness (Mantani et al., 2014). In summary, experimental and human clinical data indicate 
that B cells play a very important role in atherosclerosis.  
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1. Follicular B cells  
The majority of circulating B cells are derived from splenic FOB cells in both mice 
(B220+CD23hiCD21lo) and humans (B220+CD27-) (Pillai and Cariappa, 2009). FO B cells 
originate from transitional B cells that have successfully escaped bone marrow selection. The 
major factor that determines the differentiation fate of transitional B cells towards FO B cells 
is the B cell receptor (BCR) signalling strength. Several studies have shown that FOB cells 
require strong self-antigen mediated BCR signalling as compared to MZ B cells for their 
development (Pillai and Cariappa, 2009). We have recently challenged this paradigm by 
showing that decreasing BCR signalling restricts MZB and concomitantly promotes FOB cell 
differentiation (Tsiantoulas et al., 2017b). To date, there are no experimental studies that 
have directly and specifically investigated the role of FOB cells in atherosclerosis. 
Caligiuri et al. demonstrated that adoptive transfer of splenic B cells into splenectomised 
atherosclerosis-prone ApoE-/- mice reversed the splenectomy-induced acceleration of 
atherosclerosis (Caligiuri et al., 2002). In agreement with this, Doran et al., reported 
decreased atherosclerosis in µMT/ApoE-/- mice upon adoptive transfer of splenic B-2 cells 
isolated from ApoE-/- donors (Doran et al., 2012). Furthermore, we have recently shown that 
atherosclerotic mice lacking secreted IgM (sIgM-/-) develop increased atherosclerosis due to 
an accumulation of high IgE antibody levels. We also showed that these mice exhibit 
reduced expression of the low affinity receptor for IgE (CD23) on FOB cells, resulting in 
reduced clearance of IgE antibodies (Tsiantoulas et al., 2017a). Taken together and 
considering that FO B cells account for approximately 80% of total splenic B cells 
(Baumgarth, 2011; Tsiantoulas et al., 2014) one could hypothesize that FO B cells exhibit a 
protective effect in atherosclerosis. However, it has been reported that transfer of splenic B-2 
cells into lymphocyte-deficient Rag2-/-γ-chain-/-ApoE-/- or µMT/ApoE-/- recipients enhanced 
atherosclerosis (Kyaw et al., 2010). Additional studies performed by us and others, which 
evaluated the effect of B2 cell subsets in atherosclerosis, also supported a proatherogenic 
role for FOB cells. Treatment of hypercholesterolemic ApoE-/- and Ldlr-/- mice with anti-CD20 
antibody, which preferentially depletes B-2 cells, led to decreased atherosclerosis (Ait-
Oufella et al., 2010; Kyaw et al., 2010). Also, BAFFR deficiency in ApoE-/- and Ldlr-/- mice, or 
B-2 cell depletion using anti-BAFFR blocking antibody, limit the development of 
atherosclerosis (Kyaw et al., 2013, 2012; Sage et al., 2012), further supporting an 
atherogenic role for FO B cells. The atheroprotective effect of B-2 cell depletion was 
suggested to be mediated via suppression of proatherogenic T cell responses (Ait-Oufella et 
al., 2010; Sage et al., 2012). However, B-2 cells and most likely FO B cells may also promote 
atherosclerosis in the absence of T cells, via secretion of proinflammatory cytokines (Kyaw et 
al., 2012; Tay et al., 2016).  
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Overall, the aforementioned studies - though indirectly - support a proatherogenic role for 
FOB cells. Nevertheless, the effect of FO B cells may be influenced by their “inflammatory 
experience” such as previous antigen encountering that could ultimately result in faster and 
more efficient response to a hyperlipidemic milieu. As mentioned above, in contrast to Kyaw 
et al. (Kyaw et al., 2012), Doran and colleagues reported decreased atherosclerosis upon 
transfer of splenic B-2 cells (Doran et al., 2012). In the former study, wild-type mice B-2 cells 
were transferred, while in the latter the injected B-2 cells were isolated from ApoE-/- donors. 
Therefore, the inflammatory milieu or the previous ‘experience’ of the B cells may be an 
important factor in determining the role of FO B cells in atherosclerosis. This is also 
corroborated in splenectomised ApoE-/- mice, where the protective effect of splenic B cell 
transfer was stronger when the donor cells were derived from old ApoE-/- compared to young 
ApoE-/- donors (Caligiuri et al., 2002). Another important issue may be related to the quality 
(FO B cells versus MZ B cells versus Bregs) and extent of B cell reconstitution in an 
immunodeficient environment, and to subtle but determinant changes in cytokines and 
growth factors. For example, B cell deficient mice show very high BAFF levels, which may 
differentially alter the properties of the transferred B cells. Indeed, we have recently shown 
that the pro-atherogenic effect of B cell reconstitution in ApoE-/-/Baffr-/- mice (high BAFF 
environment) is lost when mice are infused with angiotensin II, due to a switch of the 
transferred B cells to a regulatory IL-10-producing phenotype, dependent on a synergistic 
effect of BAFF and angiotensin II (Ponnuswamy et al., 2017). Thus, FO B cells may exhibit 
different properties in atherosclerosis depending on the state of inflammation and the local 
microenvironment. B cells in SLE and RA, 2 diseases that predispose to premature 
atherosclerosis and increased CVD risk (Nurmohamed et al., 2015), may acquire a 
proinflammatory background that promotes the proatherogenic role of FO B cells. In 
conclusion, further studies are required to pinpoint the role of FO B cells in atherosclerosis. 
 
2. Marginal zone B cells  
MZ B cells are positioned at strategic sites in the outer white pulp of the spleen. Their 
development requires their migration to the marginal sinus where they become retained, pre-
activated and where they acquire the ability to self-renew and survive for a whole life-span 
(Pillai et al., 2005). While they lack circulating properties, they can shuttle from the MZ to the 
follicle (Cinamon et al., 2008). Given their low threshold for activation, proliferation and 
differentiation into antibody-secreting cells, MZ B cells are vigorously engaged in early 
immune responses, for example by rapidly responding to encounter with blood borne 
pathogens (Cerutti et al., 2013). The first two studies indirectly suggesting a potential role of 
MZB in atherosclerosis were published 2 years ago. In one of those studies, MZB cell 
numbers were decreased in WT mice compared to aged ApoE-/- mice. The authors 
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hypothesized that in ApoE-/- mice, MZB cells apoptosis was dampened due to impaired iNKT 
activation (decreased IL4 and IFNγ) (Soh et al., 2016). However, a potential bias might be 
the possible contribution of ApoE itself to MZB function. Indeed, this gene is highly 
expressed in MZB cells (Nus et al., 2017) and the ApoE receptor is not only important for 
reverse cholesterol transport but also for mediating pathways of lipid antigen presentation 
(van den Elzen et al., 2005). In the second study, the authors assumed that MZB cells were 
most probably atheroprotective by secreting anti-oxidation specific epitope (OSE) antibodies 
of the IgM subtype in response to sterile inflammation induced by apoptotic cells. However, 
the authors could not exclude that B-1 cells were responsible for this phenotype (Grasset et 
al., 2015). Interestingly, they also found that apoptotic cell injections decreased cholesterol 
levels in a B cell dependent manner. MZB cells are able to take up OxLDL (unpublished data 
and Grasset et al. PNAS 2015) in a hypercholesterolemic environment, but the impact of this 
process is still unexplored. MZ B cells also express high levels of CD36 (Zhang et al., 2007) 
and up-regulate CD36, Abcg1, and Abca1 in response to a high cholesterol diet (HCD) (Nus 
et al., 2017). Furthermore, BAFF overexpression, which notably leads to an expansion of MZ 
B cells (Mackay, JEM, 1999), results in strongly decreased plasma cholesterol levels 
accompanied by decreased lesion size in HCD-fed Apoe-/- mice (Jackson et al., 2016). It is 
then interesting to explore the potential role that MZB cells could play in cholesterol 
metabolism and whether this can be harnessed to develop new strategies to fight 
atherosclerosis.   
We have now demonstrated using an atherogenic mouse model which specifically lacks MZB 
cells that this B-2 cell subset is atheroprotective, and that the atheroprotective effect is 
mediated through the control of T follicular helper cells (Tfh) (Nus et al., 2017) (a T cell 
subset previously suggested to be atherogenic (Clement et al., 2015)). In response to a 
HCD, MZB cells migrate into the T cell zone where they bind to pre-Tfh, through PDL1-PD1 
interaction, impairing their motility and activation. This finding brings important conceptual 
changes to our understanding of the immune mechanisms of atherosclerosis, but also 
suggests that current strategies such as rituximab, belimumab and epratuzumab, that 
deplete mature B2 cells in patients with auto-immune diseases, should be evaluated for their 
impact on CV risk because they deplete both FO and MZ B cells. 
In humans, a subset of human memory B cells resemble MZ-like cells 
(CD27+IgM+IgD+CD21+Cd1d+), and MZ-like B cells have been detected in the spleen, tonsils, 
lymph nodes, Peyer´s patches, and the circulating blood (Weller et al., 2004). This offers a 
particularly interesting opportunity for investigating experimental data in the human disease 
setting. We have demonstrated that human splenic and circulating MZ-like cells express high 
levels of PDL1 (Nus et al., 2017), a potent immunoregulatory ligand in several disease 
settings, including atherosclerosis and cancer.  
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3. B-1 B cells 
 
There is a growing consensus that B-1 cells exhibit an atheroprotective effect (Tsiantoulas et 
al., 2014). B-1 cells, which are divided into B-1a and B-1b subsets predominately localize in 
the peritoneum and pleural cavities. In contrast to B-2 cells, B-1 cells are derived from fetal 
liver and they maintain their numbers by self-replenishment. Peritoneal B-1 cells are 
responsible for the production of natural IgM antibodies in a T cell independent manner 
(Baumgarth, 2011), which increases greatly when these cells migrate to the spleen (Choi et 
al., 2012). Congenitally asplenic or splenectomised mice, which develop increased 
atherosclerosis (Caligiuri et al., 2002) have strongly reduced peritoneal B-1a cell numbers 
(Wardemann et al., 2002). Kyaw et al.  showed that adoptive transfer of sIgM producing B-1a 
cells - but not sIgM-/- B-1a cells -  into splenectomised ApoE-/- mice, reversed their 
accelerated atherosclerosis (Kyaw et al., 2011). These data suggest that B-1a cells exhibit 
their atheroprotective properties via production of natural IgM, which in naïve mice make up 
for approximately 80% of total IgM antibody levels. In agreement with this, Ldlr-/- sIgM-/- mice 
develop accelerated atherosclerosis (Lewis et al., 2009; Tsiantoulas et al., 2017a). 
Furthermore, we have recently shown that mice lacking sialic acid-binding immunoglobulin-
like lectin G, which develop particularly high numbers of peritoneal B-1a cells and increased 
levels of total IgM antibodies (Hoffmann et al., 2007), are significantly protected against 
atherosclerosis (Gruber et al., 2016).  
A large part of IgM antibodies (>35%) is directed against OSE which are present in apoptotic 
cells and cellular debris (Chou et al., 2009; Tsiantoulas et al., 2015). Notably, OSE are also 
present in OxLDL, which - similar to apoptotic debris - is recognized by different OSE-specific 
natural IgM antibodies such as T15/E06 (Tsiantoulas et al., 2012). In line with this, 
cholesterol-fed atherosclerosis-prone mice immunized with heat-killed S. pneumoniae, 
developed strongly increased T15/E06 antibodies and decreased atherosclerosis (Binder et 
al., 2003). However, it is likely that other OSE-specific IgM directed against PC epitopes 
antibodies may also contribute to the atheroprotective effect in the latter study (Centa et al., 
2016). Similar to the protective capacity of B-1a cells, B-1b cell injection into ApoE-/- Rag1-/-
mice resulted in decreased lesion formation compared to PBS injected controls (Rosenfeld et 
al., 2015). However, the underlying mechanism by which B-1b cells confer an 
atheroprotective effect remains elusive. 
The studies above suggest that expansion of B-1 cells, which are also suggested to be 
present in humans and are defined as CD20+CD27+CD43+CD70- (Griffin et al., 2011), may be 
a therapeutic approach against atherosclerosis. However, innate response activator (IRA) B 
cells which are derived from B-1a cells (Rauch et al., 2012) and are increased in the spleen 
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of patients with symptomatic CVD, have been shown to aggravate atherosclerosis 
(Hilgendorf et al., 2014). Therefore, some therapeutic strategies, which aim to expand B-1 
cells may trigger unwanted effects that would confer a proatherogenic effect. For example, 
triggering TLR4 signalling, which facilitates the atheroprotective properties of B-1a cells 
(Hosseini et al., 2016) will also lead to expansion of the proatherogenic IRA B cells (Rauch et 
al., 2012). Therefore, the identification of molecular pathways that allow the selective 
expansion of B-1 cells would be of great interest. Interestingly, it has been recently 
demonstrated that expression of the transcription factor Bhlhe41 in B cells is specifically 
required for the development and self-renewal of B-1a cells (Browning, 2006). Further 
studies are needed to identify a precise approach to enhance the protective properties of B-1 
cells in atherosclerosis. 
 
4. B regulatory cells 
 
Bregs exhibit immune-suppressive and regulatory functions triggered by an inflammatory 
stimulus. They are present in very low levels in naïve mice but their numbers are 
substantially increased in response to pro-inflammatory signals like IL6, IL1β, IL21, BAFF 
and GM-CSF (reviewed in (Rosser and Mauri, 2015)). They secrete high amounts of 
immunosupressive cytokines like IL10 and IL35, which favour an anti-inflammatory Treg 
response and limit pro-inflammatory Th1 and Th17 responses (reviewed in (Fillatreau, 
2016)). It is believed that Bregs arise from different B cell subsets, and not from a common 
progenitor. However, a transcriptomic signature that determines Breg differentiation is yet to 
be identified. B10 are IL10-producing Bregs cells enriched in the CD5hiCD1dhi B cell 
population but are also found in transitional 2-MZ progenitors (T2-MZP), Tim1+ B cells, some 
CD138+ plasma cells, and some plasmablasts. They play a protective role in several murine 
models of autoimmune diseases like experimental autoimmune encephalomyelitis (EAE), 
colitis and arthritis. Nevertheless, their role in atherosclerosis is still under debate. In 
hypercholesterolemic ApoE-/- mice, T2-MZP B10 cells are significantly increased compared 
to WT mice and their adoptive transfer in an arterial injury model in ApoE-/- mice reduced 
lesion size in a IL-10-dependent manner (Strom et al., 2015). On the other hand, 
experiments performed in our lab using a B cell specific IL10 deletion model in Ldlr-/- mice 
showed that B10 deletion had no effect on the development of atherosclerosis (Sage et al., 
2015). These discrepancies could be due to different animal strains (ApoE-/- vs Ldlr-/-) and 
experimental conditions (arterial injury vs. diet-induced atherosclerosis). Indeed, recent 
studies from our lab indicate that boosting of B10 cells in defined settings, such as a high 
BAFF/high angiotensin II environment, may endow the cells with atheroprotective properties 
(Ponnuswamy et al., 2017). Furthermore, Bregs may display IL10-independent 
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immunosuppressive properties through the expression of GITRL, PDL1, IL35, or FasL 
(reviewed in (Ray et al., 2015)), which is worth exploring in the context of atherosclerosis. 
In humans, two Breg subsets have been identified, CD19+CD24hiCD38hiCD1hi and 
CD19+CD24hiCD27+ Bregs. Only one study examined the number and state of activation of 
CD19+CD24hiCD38hi Bregs in the context of atherosclerosis. Patients with myocardial 
infarction or stable angina had significantly decreased CD19+CD24hiCD38hi cell numbers 
compared to healthy controls. Those patient ‘Bregs’ also had impaired IL10 production upon 
activation with CpG and CD40L (Dumitriu et al., 2017). These are interesting results. 
However, further validation experiments are needed before reaching any definitive 
conclusion. 
 
Towards a translational strategy 
 
Altered B cell immunity is a cardinal factor in the pathology of rheumatic diseases 
(Browning, 2006), such as SLE and RA (Nurmohamed et al., 2015). In 2011, FDA approved 
an anti-soluble BAFF blocking antibody (Belimumab) as a treatment in SLE patients. 
Although the effect of soluble BAFF in atherosclerosis is not known, one could hypothesize 
based on the atheroprotective effect of BAFFR deletion or blockage in mice (Kyaw et al., 
2013, 2012; Sage et al., 2012) that Belimumab treatment may also reduce atherosclerosis 
via depletion of proatherogenic conventional B cells. However, as mentioned above 
atherosclerosis-prone mice that express particularly increased levels of circulating BAFF 
exhibit reduced plasma cholesterol levels (Jackson et al., 2016). Thus, BAFF neutralization 
may affect cholesterol metabolism in an unwanted manner.  
Furthermore, considering the protective effect of a mouse anti-CD20 treatment in 
atherosclerotic mice, it would be particularly interesting to investigate the effect of Rituximab, 
widely used for the treatment of RA patients, on CVD risk. However, it is also important to 
mention that long-term B cell depletion could result in increased infection risk due to 
compromised humoral immunity. Therefore, more studies are needed in order to identify the 
mechanistic feature of the B cell machinery that affects atherosclerotic CVD. Finally, 
addressing the CVD risk associated with B cell targeting agents will not only improve our 
understanding of the role of B cell immunity in CVD but will also help the development of 
new, more precise and effective therapeutic options against this wide-spread disease.  
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Figure 1. B cell subsets that impact atherosclerosis. B cells are divided into two major 
subsets, the innate-like B-1 and conventional B-2 cells. B-1 cells consist of B-1a and B-
1b subsets that are distinguished based on the surface receptor repertoire with the most 
prominent difference the presence of the CD5 receptor on B-1a cells. Both B-1a and B-
1b cells confer an atheroprotective effect, which is likely mediated via natural IgM 
production. On the other hand, the B-1a derived IRA cells promote atherosclerosis via 
instructing proatherogenic Th1 responses. The role of Bregs, which are major producers 
of IL-10 and IL-35, in plaque formation remains under debate. B-2 cells, which account 
for the vast majority of mature B cells, consist of FO and MZ B cells that display 
distinct levels of surface receptors such as CD23 and CD21. MZ B cells exhibit 
atheroprotective properties via regulation of Tfh homeostasis in hyperlipidemic 
conditions. A specific depletion of B-2 cells via anti-CD20 antibody treatment results in 
reduced atherosclerosis suggesting that FO B cells (the larger subset of B-2 cells) 
display a proinflammatory role in atherosclerosis. Anti-BAFF antibody treatment 
(Belimumab), which similar to Rituximab (human anti-CD20) depletes conventional B-
2 and IRA cells, is used in the clinic. However, the effect of belimumab in 
atherosclerosis remains elusive. IRA; innate response activator, Bregs: B regulatory 
cells, FO; follicular, MZ; marginal zone. 
